A biotechnology company that discovers, develops, and commercializes peptide-based medicines, with a focus on gastrointestinal and metabolic diseases. The company's portfolio includes Zegalogue for severe hypoglycemia treatment and Dasiglucagon-based therapies, with pipeline candidates in clinical development.